The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 533 KB) and Technical Notes (PDF, 752 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 1.20
Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity Females, Total U.S., 2009-2011
Site | All Races | Whites | Blacks | ||||||
---|---|---|---|---|---|---|---|---|---|
Percent | 95% Confidence Interval |
Percent | 95% Confidence Interval |
Percent | 95% Confidence Interval |
||||
Low | High | Low | High | Low | High | ||||
All Sites | 19.26 | 19.22 | 19.30 | 19.41 | 19.37 | 19.45 | 19.37 | 19.25 | 19.50 |
Oral Cavity and Pharynx | 0.18 | 0.18 | 0.19 | 0.18 | 0.18 | 0.19 | 0.15 | 0.13 | 0.16 |
Esophagus | 0.21 | 0.21 | 0.22 | 0.21 | 0.21 | 0.22 | 0.22 | 0.20 | 0.23 |
Stomach | 0.33 | 0.32 | 0.33 | 0.29 | 0.28 | 0.29 | 0.55 | 0.52 | 0.57 |
Colon and Rectum | 1.85 | 1.84 | 1.87 | 1.81 | 1.79 | 1.82 | 2.21 | 2.16 | 2.26 |
Liver and Intrahepatic Bile Duct | 0.47 | 0.46 | 0.48 | 0.44 | 0.44 | 0.45 | 0.51 | 0.49 | 0.53 |
Pancreas | 1.32 | 1.31 | 1.33 | 1.31 | 1.29 | 1.32 | 1.50 | 1.46 | 1.54 |
Larynx | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.07 | 0.06 | 0.07 |
Lung and Bronchus | 4.95 | 4.93 | 4.97 | 5.14 | 5.11 | 5.16 | 4.15 | 4.09 | 4.21 |
Melanoma of the Skin | 0.21 | 0.21 | 0.22 | 0.24 | 0.24 | 0.25 | 0.05 | 0.04 | 0.05 |
Breast | 2.72 | 2.70 | 2.74 | 2.69 | 2.67 | 2.71 | 3.26 | 3.21 | 3.32 |
Cervix Uteri | 0.23 | 0.22 | 0.23 | 0.21 | 0.20 | 0.21 | 0.38 | 0.37 | 0.40 |
Corpus and Uterus, NOS | 0.57 | 0.56 | 0.58 | 0.53 | 0.53 | 0.54 | 0.89 | 0.86 | 0.92 |
Ovary | 0.98 | 0.97 | 0.99 | 1.02 | 1.01 | 1.03 | 0.76 | 0.73 | 0.78 |
Urinary Bladder | 0.34 | 0.34 | 0.35 | 0.35 | 0.34 | 0.35 | 0.35 | 0.33 | 0.37 |
Kidney and Renal Pelvis | 0.35 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.32 | 0.30 | 0.34 |
Brain and Other Nervous System | 0.40 | 0.39 | 0.41 | 0.43 | 0.43 | 0.44 | 0.22 | 0.21 | 0.24 |
Thyroid | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 | 0.08 |
Hodgkin Lymphoma | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 | 0.03 | 0.02 | 0.03 |
Non-Hodgkin Lymphoma | 0.69 | 0.69 | 0.70 | 0.73 | 0.72 | 0.74 | 0.40 | 0.38 | 0.42 |
Myeloma | 0.38 | 0.37 | 0.38 | 0.35 | 0.34 | 0.35 | 0.64 | 0.62 | 0.67 |
Leukemia | 0.72 | 0.72 | 0.73 | 0.75 | 0.74 | 0.76 | 0.57 | 0.55 | 0.59 |
Acute Lymphocytic Leukemia | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 |
Chronic Lymphocytic Leukemia | 0.15 | 0.15 | 0.16 | 0.16 | 0.15 | 0.16 | 0.12 | 0.11 | 0.13 |
Acute Myeloid Leukemia | 0.28 | 0.27 | 0.28 | 0.29 | 0.29 | 0.30 | 0.19 | 0.18 | 0.21 |
Chronic Myeloid Leukemia | 0.04 | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 |
Site | for Asians/ Pacific Islanders |
American Indians/ Alaska Nativesa |
Hispanicsb | ||||||
---|---|---|---|---|---|---|---|---|---|
Percent | 95% Confidence Interval |
Percent | 95% Confidence Interval |
Percent | 95% Confidence Interval |
||||
Low | High | Low | High | Low | High | ||||
All Sites | 16.84 | 16.52 | 17.16 | 15.93 | 15.28 | 16.62 | 15.81 | 15.63 | 15.99 |
Oral Cavity and Pharynx | 0.20 | 0.17 | 0.25 | 0.16 | 0.10 | 0.28 | 0.14 | 0.12 | 0.16 |
Esophagus | 0.16 | 0.13 | 0.20 | 0.23 | 0.15 | 0.37 | 0.15 | 0.13 | 0.18 |
Stomach | 0.99 | 0.90 | 1.09 | 0.42 | 0.31 | 0.58 | 0.67 | 0.63 | 0.71 |
Colon and Rectum | 1.95 | 1.83 | 2.09 | 1.92 | 1.67 | 2.21 | 1.71 | 1.64 | 1.78 |
Liver and Intrahepatic Bile Duct | 1.15 | 1.07 | 1.24 | 0.71 | 0.58 | 0.90 | 0.89 | 0.85 | 0.94 |
Pancreas | 1.45 | 1.36 | 1.56 | 0.98 | 0.80 | 1.20 | 1.35 | 1.30 | 1.42 |
Larynx | 0.02 | 0.01 | 0.04 | 0.03 | 0.01 | 0.13 | 0.03 | 0.02 | 0.05 |
Lung and Bronchus | 3.39 | 3.25 | 3.53 | 3.70 | 3.39 | 4.05 | 2.23 | 2.16 | 2.31 |
Melanoma of the Skin | 0.05 | 0.04 | 0.09 | 0.06 | 0.03 | 0.16 | 0.10 | 0.08 | 0.11 |
Breast | 1.75 | 1.65 | 1.87 | 1.73 | 1.51 | 2.00 | 2.05 | 1.98 | 2.12 |
Cervix Uteri | 0.24 | 0.21 | 0.29 | 0.31 | 0.23 | 0.45 | 0.31 | 0.29 | 0.34 |
Corpus and Uterus, NOS | 0.46 | 0.41 | 0.52 | 0.39 | 0.30 | 0.54 | 0.51 | 0.48 | 0.54 |
Ovary | 0.69 | 0.63 | 0.75 | 0.83 | 0.68 | 1.03 | 0.82 | 0.78 | 0.86 |
Urinary Bladder | 0.25 | 0.20 | 0.31 | 0.14 | 0.09 | 0.25 | 0.26 | 0.24 | 0.30 |
Kidney and Renal Pelvis | 0.27 | 0.22 | 0.33 | 0.56 | 0.43 | 0.75 | 0.37 | 0.35 | 0.41 |
Brain and Other Nervous System | 0.24 | 0.21 | 0.28 | 0.16 | 0.11 | 0.26 | 0.31 | 0.28 | 0.33 |
Thyroid | 0.16 | 0.13 | 0.21 | 0.06 | 0.02 | 0.16 | 0.11 | 0.09 | 0.13 |
Hodgkin Lymphoma | 0.02 | 0.01 | 0.05 | 0.01 | 0.00 | 0.10 | 0.04 | 0.03 | 0.05 |
Non-Hodgkin Lymphoma | 0.67 | 0.61 | 0.75 | 0.47 | 0.36 | 0.64 | 0.73 | 0.69 | 0.77 |
Myeloma | 0.24 | 0.21 | 0.28 | 0.32 | 0.23 | 0.47 | 0.38 | 0.35 | 0.41 |
Leukemia | 0.57 | 0.51 | 0.64 | 0.36 | 0.27 | 0.51 | 0.60 | 0.57 | 0.65 |
Acute Lymphocytic Leukemia | 0.04 | 0.03 | 0.06 | 0.03 | 0.01 | 0.12 | 0.06 | 0.05 | 0.07 |
Chronic Lymphocytic Leukemia | 0.05 | 0.03 | 0.08 | 0.06 | 0.02 | 0.18 | 0.08 | 0.07 | 0.11 |
Acute Myeloid Leukemia | 0.29 | 0.25 | 0.34 | 0.17 | 0.11 | 0.28 | 0.23 | 0.21 | 0.25 |
Chronic Myeloid Leukemia | 0.04 | 0.02 | 0.07 | 0.01 | 0.00 | 0.10 | 0.03 | 0.02 | 0.04 |
Footnotes:
Devcan Version 6.8.0, August 2014, National Cancer Institute (https://surveillance.cancer.gov/devcan/).
Source: NCHS public use data file for the total US.
a Underlying mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.
b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.